Applied Therapeutics gets FDA priority review for govorestat in classic galactosemia
The FDA has set a PDUFA target action date of 28 August 2024 for the investigational, Aldose Reductase…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
29 Feb 24
The FDA has set a PDUFA target action date of 28 August 2024 for the investigational, Aldose Reductase…
29 Feb 24
Greenway Patient Connect aims to support three daily elements of a patient’s experience - access, communication, and readiness.
29 Feb 24
Biofourmis' care-at-home solutions include wearable devices, digital platforms, and in-home services orchestration technology.
29 Feb 24
FDA-approved generic provides cost-effective option for treating cancer
28 Feb 24
Under the agreement, Italy-based Zambon will seek regulatory approval and market IPX203 in the European Union, UK, and…
28 Feb 24
AbbVie seeks approval for epcoritamab to treat adults with relapsed or refractory (R/R) FL after two or more…
28 Feb 24
The FDA approved Exblifep (cefepime/enmetazobactam) based on a comprehensive set of clinical data showing the drug's efficacy against…
28 Feb 24
The BTD for NVL-520 is based on the preliminary safety and activity of NVL-520 in heavily pretreated patients…
27 Feb 24
Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups
26 Feb 24
In the trial, a 16-week course of omalizumab enhanced the quantity of peanut, tree nut, egg, milk, and…